Priscilla Schaffer

Title: Priscilla Schaffer: Innovator in Herpes Simplex Virus Research

Introduction

Priscilla Schaffer is a notable inventor based in Tucson, AZ (US). She has made significant contributions to the field of virology, particularly in the study of herpes simplex virus type 1 (HSV-1). Her innovative work has implications for the treatment and prevention of HSV-1 infections.

Latest Patents

Priscilla Schaffer holds a patent for a mutant herpes simplex virus that includes a mutant protein involved in replication. This mutant virus is designed to impair or inhibit the replication of HSV-1. The innovation involves a mutation in at least one phosphorylation site of a protein that plays a role in replication, which helps to prohibit or impair the replication of HSV-1 and reduce the clinical severity of HSV-1-mediated diseases. The mutant protein, specifically a mutant ICP0, has reduced or inhibited posttranslational phosphorylation. This mutant HSV-1 and/or mutant ICP0 can be utilized in vaccines or other pharmaceutical preparations aimed at treating, limiting, and preventing HSV-1 infections. Additionally, they can be employed in the screening and development of anti-HSV-1 agents.

Career Highlights

Throughout her career, Priscilla Schaffer has worked with esteemed institutions such as the University of Kansas and Beth Israel Deaconess Medical Center, Inc. Her research has been pivotal in advancing the understanding of HSV-1 and developing potential therapeutic strategies.

Collaborations

Priscilla has collaborated with notable professionals in her field, including David J. Davido. Their joint efforts have contributed to the advancement of research in herpes simplex virus.

Conclusion

Priscilla Schaffer is a pioneering inventor whose work on herpes simplex virus has the potential to transform treatment options for HSV-1 infections. Her innovative research continues to pave the way for future advancements in virology.